분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-08-06 09:53:04 , Hit : 1301
 Roche says to buy Danish Santaris for up to $450 million


ZURICH Mon Aug 4, 2014 6:23pm BST

08/05/2014
ZURICH (Reuters) - Roche (ROG.VX) said on Monday it will buy Santaris Pharma, a privately-held Danish biotech company that has developed a new designer molecule, for up to $450 million in cash.

Santaris, which was founded through a merger of two companies in 2003, develops drugs which work by blocking or "silencing" microRNAs -- tiny strands of RNA, or ribonucleic acid, that help turn genes into proteins.

"This new class of medicines has the potential to address difficult to treat diseases in a range of therapeutic areas," the Basel-based drugmaker said in a statement.

In the hotly pursued RNA interference field, Santaris has developed a new class of drug, known as Locked Nucleic Acid (LNA), which fine tunes the action of genes and has been shown to cut cholesterol in monkeys.

Santaris, which had previously secured funding from Roche to conduct research beyond 2014, is the second acquisition in short order for the Swiss firm, which splashed out $1.725 billion for Seragon Pharmaceuticals last month.

Since acquiring Genentech for $46.8 billion in 2009, Roche has earned a reputation as a disciplined acquirer, prepared to walk away from potential deals rather than overpay.

Chief Executive Severin Schwan abandoned a $6.8 billion deal to buy U.S gene sequencing company Illumina in 2012 and has snapped up a couple of smaller diagnostic companies this year instead of pursuing multi-billion deals.

Roche has also partnered with various companies to develop antibiotics and said in May that it would work with Inception Sciences Inc and Versant Ventures on a new company to develop therapies for patients with multiple sclerosis.

Prior to the Roche acquisition, Santaris' part-owner, Danish venture capital firm Sunstone, had been eyeing a listing in the United States.

The terms of the deal, expected to close later this month, include $250 million upfront in cash with another $200 million pending the achievement of drug development targets, Roche said.

Other Santaris partners include Bristol Myers Squibb (BMY.N) and GlaxoSmithKline Plc (GSK.L).


(Reporting By Katharina Bart; editing by David Clarke)







947   Gilead Licenses Hepatitis Therapy in India Amid Price Criticism  이성욱 2014/09/17 1703
946   자신의 유전체를 해체하고 재조립하는 단일 세포  이성욱 2014/09/15 1448
945   STAP세포논문철회에서 새롭게 밝혀진 사실들  이성욱 2014/09/15 1305
944   질 속의 미생물(vaginal microbe)이 생성하는 새로운 항생제  이성욱 2014/09/15 1480
943   자연계의 항생제 공장에서 스위치 역할을 하는 소분자 물질  이성욱 2014/09/04 1945
942   Daclatasvir (Daklinza) for Chronic Hepatitis C Cleared in EU  이성욱 2014/08/29 2133
941   소아암 촉진 유전자 Lin28b 규명  이성욱 2014/08/18 1459
940   바이러스를 저지시키는 방법  이성욱 2014/08/15 1650
939   Sovaldi forces Incivek off the hep C market as Vertex calls it quits  이성욱 2014/08/15 1509
938   Genetically 'edited' fruit could soon hit supermarket shelves  이성욱 2014/08/15 1324
937   암 연구를 위한 새로운 유전자 편집 기술  이성욱 2014/08/11 1449
936   New Guide RNAs for CRISPR Can Double the Targetable Genome  이성욱 2014/08/09 2141
935   일본의 뇌과학자 요시키 사사이의 죽음  이성욱 2014/08/08 1766
  Roche says to buy Danish Santaris for up to $450 million  이성욱 2014/08/06 1301
933   뇌종양이 남성에서 더 흔한 이유?  이성욱 2014/08/06 1654
932   서아프리카의 에볼라 사태, 전 지구적 재앙으로 이어질 수 있을까?  이성욱 2014/08/06 1531
931   가장 중요한 감시자 p53의 새로운 기능!  이성욱 2014/08/05 1420
930   HIV를 죽게하는 강제적인 돌연변이  이성욱 2014/08/04 1460
929   「신약승인을 위한 임상시험 데이터」, 공개해야 하나?  이성욱 2014/08/01 1457
928   miRNA를 이용한 계통발생 분석의 문제점  이성욱 2014/08/01 1667

[이전 10개] [1]..[11][12][13][14][15][16] 17 [18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN